Trimethylaminuria (TMAU) is a rare metabolic condition characterised by an unpleasant smell resembling rotting fish. Currently, the only measure of treatment efficacy is urine trimethylamine levels which do not always reflect the patient's experience of symptoms. A literature review did not find a specific tool to assess treatment efficacy from the patient's perspective. The aim of this study was to develop an assessment tool to provide a quantitative measure of treatment efficacy in patients diagnosed with TMAU before and after treatment and assess its acceptability (feasibility of use and face and content validity) to people living with TMAU.
| INTRODUCTION
Trimethylaminuria (TMAU), also known as fish odour syndrome, is a rare metabolic and psychologically disabling condition where affected individuals excrete a foul odour resembling the smell of rotting fish, faeces or garbage. 1 The true prevalence of this disorder is unknown. 2 While primary TMAU is more prevalent, secondary cases of TMAU have been described in all parts of the world affecting both genders. 3 In primary TMAU trimethylamine (TMA), which derives from the intestinal bacterial degradation of food rich in choline, lecithin, and carnitine, is excreted in urine, sweat, breath, and other bodily secretions 4 due to a fault in Flavin monooxigenate 3 enzyme (FMO3) which otherwise converts TMA into odourless trimethylamine N-oxide (TMANO). 2 Conversely, in secondary TMAU TMA is excreted due to hormonal modulation, liver damage, renal disease, or viral infection. 5 In the absence of physical symptoms, diagnosis of TMAU is established by measuring oxidizing ratios of TMA and TMANO in urine 4 or genetic testing. 2 Nevertheless, diagnosis of the condition is challenging and an assumption can be made that it is a psychological problem. 2 TMAU has been shown to negatively affect the psychological and social well-being of the affected individuals 6 and may result in depression, anxiety, social isolation, difficulties with employment, 2 and potentially attempted suicide. 7 Currently there is no cure for TMAU, however, life style changes such as reducing the dietary precursors of TMA are recommended as first line management of this condition. 1 The malodourous smell has been variously reported to be alleviated by antibiotics, laxatives, riboflavin, charcoal, copper chlorophyllin, shampoos and soaps with a pH between 5.5 -6.5. 3 Psychological counselling from a specialist in a safe environment has been reported by people living with TMAU to play a vital part in the management of this condition. 6, 8 Consequently, these treatments are recommended in consultation with a metabolic medicine team and its associated dietetics and counselling services. A number of articles highlight challenges in TMAU management due to the available treatment not being universally efficacious. 1, 2, 9 In clinical practice the only markers of treatment effectiveness, for example, response to antibiotics, riboflavin, or decreased intake of dietary FMO3 inhibitors, are TMA and TMA/TMANO ratios 4 , however, they do not always reflect the patient's experience of symptoms.
In these circumstances, an approach which focuses on patient-reported outcome measures (PROMs) and patientreported experience measures (PREMs) may be more appropriate to inform future TMAU treatment outcomes pre-and post-intervention. 10 PROMs and PREMs are reported to narrow the gap between the clinician's and patient's view of clinical reality as they participate in the design of care delivery themselves, a process which is also known as co-production and sees patients and clinical staff as equal partners to optimise the best outcome for each individual patient's journey.
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In this context, the aim of this study was to develop an assessment tool to provide a quantitative measure of treatment efficacy in patients diagnosed with TMAU before and after treatment and assess its acceptability (feasibility of use and face and content validity) to people living with TMAU.
| METHODS
A mixed methods sequential study, in which equal weighting to qualitative and quantitative findings was given, 12 was selected in the absence of primary research findings. 13 This involved using a modified Delphi technique 13 and semistructured interviews 14 to determine face validity of the tool, its acceptability and comprehension of the questions. The study was approved by the London-Surrey Borders Research Ethics Committee. REC reference: 17/LO/0600. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study. Proof that informed consent was obtained is available upon request. This article does not contain any studies with human or animal subjects performed by any of the authors.
| Study setting
The modified Delphi was conducted by email with eight people living with a diagnosis of TMAU, who participated in an online forum (http://www.tmau.org.uk), five medical consultants, and four dieticians, who worked in four centres for metabolic diseases in NHS hospitals in England. The interviews were conducted with three patients in two hospitals in a metropolitan region in the United Kingdom.
| Delphi study
Experts were recruited via two routes: by approaching metabolic clinicians known to the research team with a request to assist with the study and by approaching a representative from the TMAU forum located via internet searching, who gained an agreement with people with TMAU to email their contact details. They were then emailed the study information and gave consent to participate.
| Interviews
Patients attending their TMAU-related outpatient appointment were approached by their metabolic consultants at the end of the appointment who explained the study, and gave a patient information sheet and expression of interest form which clinicians passed onto K.R. if completed by the patient. K.R. then contacted the patients to arrange an interview. Written consent to participate was gained prior to the interview being conducted.
| Data collection
The modified Delphi technique was conducted by email in four rounds between November 2016 and February 2017. In round 1, the concepts of potential areas of impact of illness on a person formed initial domains of interest 15, 16 (Supporting Information, File S1) and participants were asked to list items which they thought would measure TMAU treatment efficacy within these domains. In round 2, participants were asked to rate each individual item summarised by the researchers individually (from those collected in the first round) in terms of their perceived importance to measure treatment efficacy in TMAU on a low (0) to high (10) point scale of importance. In round 3, participants were asked to rank each of the items within each domain in the order of their perceived importance from within the list of items provided to measure the effectiveness of TMAU treatment. In round 4, participants were asked to comment on the draft content of the TMAU treatment efficacy patient selfreport survey, that had been developed from analysis of round 3, including listing any statements that they continued to have any concerns with, ranking the domains headings in order of relative importance and commenting on the clarity of the instructions and the layout of the tool.
The interviews were conducted in-person (K.R.) between May and July 2017 straight after patients' clinical appointments. Interviews followed a topic guide that focused on three areas: the content of the proposed tool, ease of use of the tool, and feelings and comfort/discomfort with completing the tool. Open-ended questions were asked to allow discussion with patients. The interviews were digitally recorded and transcribed verbatim.
Prior to the interviews, the draft survey was piloted with two healthcare professionals (one working in a hospital trust pain department and one with a nursing educational background) to gain feedback on the appropriateness of the content, its layout and instructions and to reflect on the interviewing process. This process was facilitated through maintaining a personal reflective diary and critical discussions with peers and resulted in altering some of the questions on the topic guide and their order.
| Data analysis
The Delphi analysis was qualitative at each round and quantitative at rounds 2, 3, and 4. In round 1, the items put forward by participants were grouped by aligning similar items and moving them into a relevant domain in a qualitative process. The language used by participants was maintained in the items to reflect the original content. The pool of items collected in round 1 was reduced by excluding items which were rated, in round 2, below the third quartile of the median by ≥70% of participants. 17 All remaining items were re-grouped thematically by two researchers (K.R. and M.H.). In round 3, the pool of items in each domain was reduced further by excluding items ranked above the third quartile of the median. 17 In addition, the retained items were: translated into statements to make sense for the patient completing the tool and to be measurable; moved between domains for best fit; and arranged in the order of their importance according to the rankings. In round 4, the order of the overarching domains was established according to the rankings of the experts and a further qualitative process involved aligning similar items into grouped items and moving them into a relevant domain by researchers (K.R. and M.H.). A thematic analysis 18 of the qualitative data obtained from the interviews was undertaken by K.R. and M.H. and involved transcribing, familiarising with data (reading and listening), generating independent coding, indexing of transcripts, and naming themes through an iterative process with any differences resolved through discussion.
| RESULTS
Delphi and semi-structured interview participants' characteristics and response rates are presented in Table 1 .
| Generating items for the survey via the Delphi study
Round 1 generated 265 items distributed across 12 domains (Table 2 ) with the largest number of items in the "Odour affecting psychological well-being-affective" and "Odour affecting social well-being" domains. The 265 items were reduced to 76 items across 10 domains by matching them qualitatively to other items (see File S2 for the detail of item reduction). Through this process the odour affecting physical well-being, spirituality and whole person domains were removed as separate entities and the 35 items from those domains assimilated into other domains where similar concepts were already covered. Two new domains: 'healthcare professionals' and 'work/finance' were created. As the median scores for importance of all items in round 2 were above the third quartile, the 76 items were reduced to 39 items by the qualitative method (File S3). However, one item "I feel suicidal" was added by the experts in this round thus resulting in 40 items carried forward to round 3. Following round 3, the 40 items were reduced to 27, 10 items quantitatively as the median scores for importance were above the third quartile of the median and 3 items by matching qualitatively to other items. The number of domains was also reduced qualitatively from 10 to 5. Four out of five items from the "Comments from others" domain were moved to the "Mental Well-being-affective" domain. The remaining item from that domain and the items from the "Coping mechanism," "Work/finance," "Healthcare professionals" were moved to a newly created "Functional wellbeing" (File S4).
In round 4, there was no further item reduction. However, the "affective and cognitive mental well-being" domains were merged as they were perceived as a single entity by the experts and the "functional well-being domain" name was changed to "other aspects affecting your life" as it better represented the items in that domain and the final order of domains and statements were formed.
3.2 | Feasibility, acceptability, face, and content validity of the survey One theme "Need to measure TMAU impact and its challenges" emerged in relation to the content of the tool and its impact on participants and one theme "views on tool design with suggestions for minor refinement" in relation to the tool's design.
| Need to measure TMAU impact and its challenges
Feedback on the content of the tool was encouraging. Participants suggested that the domains in the assessment tool reflected their experiences with TMAU:
Participant (2): "it does pin down the experience of having TMAU … it does cover the actual smell itself and it covers the emotional affect that it has on people and yeah and it talks about the social effect which are the three main areas of TMAU."
However, it was highlighted that the assessment tool focused on the impact TMAU had on quality of life rather than on the treatment received. The participants noted that there is no cure and a limited choice of TMAU treatment thus suggesting that scores after treatment may not be different from scores before treatment. The participants emphasised the importance of support from healthcare professionals in the management of TMAU: Participant (1): "they can't do anything anymore for me but it's nice, like Dr X said today, 'I'm really sorry I can't do any more' and just making that statement, helps me feel good."
All three participants agreed that the mental well-being domain was an important concept to measure, however, they presented a different level of concern about asking people with TMAU questions on this issue. One participant was unconcerned personally, seeing it as potentially helpful to be able to express psychological issues: Participant (3): "I did not have any concerns about any of these questions and I understood why they are being asked. … I would have thought for some people it might be a relief to kind of get down and actually say that they do feel anxious or something like that."
On the other hand, another participant considered that such questions might produce a more "defensive" response: Participant (2): "You are not necessarily going to get honest answers from everyone or it may well upset some people a lot... some people would not be prepared to say yes I feel suicidal and some people may feel very guilty that they feel suicidal they are not even going to admit that (thinking)."
All participants thought that the content in the social well-being domain was relevant and appropriate to be included: Participant (3) "I think it's good questions to ask because I think this disorder does have an impact on … on social relationships… and I think they are fair questions because you cover career and relationships."
The feedback relating to the content in the odour characteristics domain was also positive. All patients thought it was relevant and appropriate to be included: Participant (1) "the first subsection, that was absolutely clear, I didn't have any problem with any that."
During the interviews participants provided TMAU narratives relating to their difficulties with achieving a diagnosis, TMAU as an illness, their perceptions on the intensity and variability of smell, restrictions on life style, impact on mental well-being, negative reactions from others, support from others and perceived effectiveness of TMAU treatment. It appeared that these narratives were triggered by completing the assessment tool or the interview.
| Views on tool design with suggestions for minor refinement
All participants provided positive feedback on the design of the assessment tool indicating no issue with its layout or length.
Participants provided suggestions to improve the introduction section, scoring instructions, and the use of asterisks. Consequently, the asterisks were removed and the instructions in each subscale were improved to remind patients that the statements related to their experience with TMAU; one statement "I am not tolerant of other attitudes" was removed from the mental well-being domain; and one statement "the odour comes from a particular part of the body" was added to the odour characteristics domain. The refined instructions of the TMAU treatment efficacy tool are presented in Figure 1 , its questions in Figure 2 and its scoring and completion guide in File S5.
| DISCUSSION
The TMAU treatment efficacy tool was co-produced by 18 experts: 8 individuals living with TMAU, 6 medical consultants, and 4 dieticians in four rounds of the Delphi process and tested with three patients. It consists of 27 items distributed across four domains: odour characteristics with 6 items, social well-being with 5 items, healthcare professionals support with 3 items, and mental well-being with 13 items which comprises 48% of the tool's content.
The evidence from the interviews reflect the findings from the Delphi study and literature confirming that items in the assessment tool relate to TMAU disorder 4, 19, 20 and importantly suggest that the items relating to feelings of depression and suicide could be emotionally provoking and sensitive to measure. 21 The evidence from the interviews also suggests that TMAU symptoms can vary from patient to patient. It seems likely that the value of the assessment tool may lie in its use by clinicians and patients to aid discussion, on highly sensitive topics that might otherwise be difficult to assess in the clinic, when patients are noted to sometimes only send indirect signals regarding emotional expression and clinicians may have low awareness or a lack of training in this area. 22 That said, screening of general hospital patients for suicide risk has previously been received positively. 23 In-clinic or at-home completion could take place prior to a consultation to help inform this patientclinician decision-making process, allowing tailoring of treatment plans to match an individual's response and preference and providing a framework to identify treatment outcomes which otherwise could go unrecognised. 11 The tool as currently designed calls for assessment at a moment in time 24 which may be coterminous with a medical outpatient review. It is recognised that measurement over a period of time is recommended in line with the measurement of constructs such as psychological well-being. 25 
| Strengths
Involving a heterogeneous sample of 18 experts 26 in the tool's development met recommendations by Okoli and Pawlowski 27 suggesting that 10 to 18 experts are sufficient to obtain a wide range of views and Sumison's 28 suggestion that 70% participant response rate is sufficient to maintain validity of study results. The response rate in the first round of the Delphi study was 100% and over 75% in the remaining three rounds, however, more importantly the representation of TMAU individuals across all rounds was greater than the representation of other experts. The mixed methods approach also enabled gaining wider perspectives which would be beyond the scope of a single research method. 12 Additionally, every effort was made to increase transferability of the findings and limiting the researcher's influence during the process: the items were aligned so that they reflected the experts' original language. 29 Furthermore, the experts were able to review the items interpreted by the researcher and comment on them
Patient Identification number:
Date:
This is an assessment tool which aims to measure how a range of symptoms associated with TMAU affect you. This assessment is carried out before and after you receive treatment from your consultant at the hospital.
Due to the potentially sensitive nature of questions, it is possible that you may experience some temporary distress arising from the completion of the questionnaire. In the event of any distress, you will be asked if you need a comfort break or if you prefer to stop completing the questionnaire. Should any distress arise, you will have support of your team at the hospital, who will also sign post you to services which can be contacted, if any distress continues after completing this questionnaire.
Below there is a list of statements about those symptoms and their impacts which you may or may not experience.
Please read each statement and circle a value between 0-10 where 0 indicates that you disagree completely with the statement at the moment of completing the assessment tool and 10 indicates that you agree completely with it. in each round of the Delphi process. 26 The transparency of data retrieval during the interviews was increased by a second researcher who read the transcripts and commented on the outcome of the analysis. 
| Limitations
Consensus levels in Delphi studies vary between 51% and 100%, 30 therefore it was recognised that the existence of consensus or no consensus did not mean the correct answer would have been found, however, statistical calculations were used to reduce items quantitatively. 26 A larger sample size of participants in the interviews may have generated more refinement of the assessment tool. However, due to low prevalence of TMAU, the sample size needed to be realistic in terms of the recruitment and data analysis requirements in a specified time period. This study was mainly focusing on the development of the assessment tool therefore the clinical phenotypes of the subjects were not collected or differentiated. However, it is envisaged that the tool, regardless of the patient's phenotype, will provide a quantitative measure of treatment efficacy before and after treatment.
The first 6 statements relate to the aspects of the odour characteristics with regards to TMAU Disagree________________________Agree 0  1  9  8  7  6  5  4  3  2  1  0  t  n  a  s  a  e  l  p  n  u  s  i  r  u  o  d  o  e  h  T   0  1  9  8  7  6  5  4  3  2  1  0  e  s  n  e  t  n  i  s  i  r  u  o  d  o  e  h  T   0  1  9  8  7  6  5  4  3  2  1  0  t  n  a  t  s  n  o  c  s  i  r  u  o  d  o  e  h  T   0  1  9  8  7  6  5  4  3  2  1  0  y  d  o  b  e  l  o  h  w  e  h  t  m  o  r  f  s  e  m  o  c  r  u  o  d  o  e  h  T   0  1  9  8  7  6  5  4  3 
| CONCLUSION
The aspects of feasibility, acceptability, face, and content validity of the tool presented in this paper represents the first step in the process of the tool's development. While further development is needed to address issues such as the time period being considered by the patient while completing the tool, and to test for the validity and reliability of the assessment tool, it may serve as a useful discussion prompt between clinicians and patients when diagnosing and treating TMAU. A patient-centred approach in the outpatient's clinic could yield more detailed information to target and tailor treatment strategies and acknowledge the psychosocial aspects of the condition from a patient perspective. Following refinement, the tool could be useful in the measurement of effect in interventions focusing on treatment efficacy in TMAU, in multicentre trials.
